EML4 and T-cell non-Hodgkin lymphoma: Besides, selective anaplastic lymphoma kinase (ALK) inhibitors is a first-line therapy for nucleophosmin (NPM)-ALK-positive T cell lymphoma and echinoderm microtubule-associated protein like 4 (EML4)-ALK-positive non-small cell lung cancer (NSCLC) [133, 134].